Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.5 USD | 0.00% | +2.23% | +2.87% |
Jul. 02 | Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer | CI |
Jun. 18 | Cantor Fitzgerald Initiates Innoviva at Overweight Rating | MT |
Financials (USD)
Sales 2024 * | 303M | Sales 2025 * | 319M | Capitalization | 1.03B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 4.14 x |
Net Debt 2024 * | 224M | Net Debt 2025 * | 145M | EV / Sales 2025 * | 3.68 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 112 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.49% |
Latest transcript on Innoviva, Inc.
1 week | +3.12% | ||
Current month | +0.61% | ||
1 month | +4.50% | ||
3 months | +8.48% | ||
6 months | +2.87% | ||
Current year | +2.87% |
Managers | Title | Age | Since |
---|---|---|---|
Pavel Raifeld
CEO | Chief Executive Officer | 40 | 20-05-19 |
Stephen Basso
DFI | Director of Finance/CFO | 58 | 23-08-20 |
Marianne Zhen
AUD | Comptroller/Controller/Auditor | 55 | 14-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 18-02-11 | |
Director/Board Member | 53 | 22-12-31 | |
Jules Haimovitz
BRD | Director/Board Member | 73 | 18-02-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.46% | 28 M€ | -4.37% | ||
0.40% | 26 M€ | -6.65% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-07-02 | 16.5 | 0.00% | 298,757 |
24-07-01 | 16.5 | +0.61% | 448,444 |
24-06-28 | 16.4 | +1.23% | 809,155 |
24-06-27 | 16.2 | -0.49% | 374,432 |
24-06-26 | 16.28 | +0.87% | 311,484 |
Delayed Quote Nasdaq, July 02, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+2.87% | 1.03B | |
+55.55% | 823B | |
+42.31% | 641B | |
-6.83% | 352B | |
+17.15% | 324B | |
+7.09% | 301B | |
+14.02% | 241B | |
+1.64% | 223B | |
+13.66% | 218B | |
+7.87% | 167B |
- Stock Market
- Equities
- INVA Stock